Featured Publications
Individualising intensive systolic blood pressure reduction in hypertension using computational trial phenomaps and machine learning: a post-hoc analysis of randomised clinical trials
Oikonomou EK, Spatz ES, Suchard MA, Khera R. Individualising intensive systolic blood pressure reduction in hypertension using computational trial phenomaps and machine learning: a post-hoc analysis of randomised clinical trials. The Lancet Digital Health 2022, 4: e796-e805. PMID: 36307193, PMCID: PMC9768739, DOI: 10.1016/s2589-7500(22)00170-4.Peer-Reviewed Original ResearchConceptsSystolic blood pressure controlBlood pressure controlIntensive systolic blood pressure controlType 2 diabetesPressure controlCardiovascular benefitsClinical trialsMajor adverse cardiovascular eventsFirst major adverse cardiovascular eventLarge randomised clinical trialsACCORD-BP trialAdverse cardiovascular eventsRandomised clinical trialsSystolic blood pressureCox regression analysisTreatment effectsHazard ratio estimatesACCORD-BPBP trialCardiovascular eventsBlood pressurePrimary outcomeStandard treatmentBaseline variablesIndex patientsA phenomapping-derived tool to personalize the selection of anatomical vs. functional testing in evaluating chest pain (ASSIST)
Oikonomou EK, Van Dijk D, Parise H, Suchard MA, de Lemos J, Antoniades C, Velazquez EJ, Miller EJ, Khera R. A phenomapping-derived tool to personalize the selection of anatomical vs. functional testing in evaluating chest pain (ASSIST). European Heart Journal 2021, 42: 2536-2548. PMID: 33881513, PMCID: PMC8488385, DOI: 10.1093/eurheartj/ehab223.Peer-Reviewed Original ResearchConceptsStable chest painChest painPrimary endpointMajor adverse cardiovascular eventsNon-fatal myocardial infarctionAdverse cardiovascular eventsStudy's primary endpointCoronary artery diseaseClinical trial populationsCox regression modelParticipant-level dataSCOT-HEARTCardiovascular eventsCause mortalityHazard ratioPatients 5Artery diseaseFunctional testingPROMISE trialTrial populationMyocardial infarctionLower incidenceStudy populationPainCollected variables
2022
Phenomapping-Derived Tool to Individualize the Effect of Canagliflozin on Cardiovascular Risk in Type 2 Diabetes.
Oikonomou EK, Suchard MA, McGuire DK, Khera R. Phenomapping-Derived Tool to Individualize the Effect of Canagliflozin on Cardiovascular Risk in Type 2 Diabetes. Diabetes Care 2022, 45: 965-974. PMID: 35120199, PMCID: PMC9016734, DOI: 10.2337/dc21-1765.Peer-Reviewed Original ResearchConceptsCanagliflozin Cardiovascular Assessment StudyMajor adverse cardiovascular eventsType 2 diabetesHazard ratioSodium-glucose cotransporter 2 inhibitorsCardiovascular disease benefitAdverse cardiovascular eventsCotransporter 2 inhibitorsEffects of canagliflozinCanagliflozin dosesCanagliflozin's effectsCardiovascular eventsCardiovascular riskPatients 5Cardioprotective effectsSGLT2 inhibitorsDisease benefitBaseline variablesOriginal trialCanagliflozinType 2DiabetesPatientsRisk estimatesEffect estimates
2018
Development and Validation of a Clinical Score for Cardiovascular Risk Stratification of Long‐Term Childhood Cancer Survivors
Oikonomou EK, Athanasopoulou SG, Kampaktsis PN, Kokkinidis DG, Papanastasiou CA, Feher A, Steingart RM, Oeffinger KC, Gupta D. Development and Validation of a Clinical Score for Cardiovascular Risk Stratification of Long‐Term Childhood Cancer Survivors. The Oncologist 2018, 23: 965-973. PMID: 29593100, PMCID: PMC6156177, DOI: 10.1634/theoncologist.2017-0502.Peer-Reviewed Original ResearchConceptsLong-term childhood cancer survivorsChildhood cancer survivorsCardiovascular risk stratificationCardiovascular mortalityCancer survivorsRisk scoreCardiovascular riskRisk stratificationRisk of CVMTreatment-related adverse eventsAdverse cardiovascular eventsRisk stratification toolSimple risk scoreCongestive heart failureCumulative incidence rateEnd Results ProgramMedian time periodPopulation-based studyHistory of lymphomaHigh-risk groupLow-risk groupSimple clinical toolHistory of radiationNon-white raceHealth care providers
2017
Pregnancy associated plasma protein-A as a prognostic biomarker of all-cause mortality and cardiovascular events in patients presenting with chest pain: a systematic review
Papanastasiou CA, Kokkinidis DG, Oikonomou EK, Mantziaris VG, Foley TR, Karamitsos TD, Waldo SW, Armstrong EJ. Pregnancy associated plasma protein-A as a prognostic biomarker of all-cause mortality and cardiovascular events in patients presenting with chest pain: a systematic review. Biomarkers 2017, 23: 1-9. PMID: 29144175, DOI: 10.1080/1354750x.2017.1397194.Peer-Reviewed Original ResearchConceptsIschemic chest painChest painCardiovascular eventsAdverse eventsShort-term adverse eventsShort-term risk stratificationAdverse cardiovascular eventsAcute coronary syndromeGroup of patientsIdentification of patientsStandardized clinical studiesElectronic databases MEDLINEFuture adverse eventsPlasma proteinsCause mortalityCoronary syndromeIschemic originRisk stratificationPrognostic valueCochrane LibraryPatient populationClinical studiesInclusion criteriaPrognostic biomarkerPain